nodes	percent_of_prediction	percent_of_DWPC	metapath
Dextroamphetamine—L-Phenylalanine—Liothyronine—hypothyroidism	0.657	1	CrCrCtD
Dextroamphetamine—Muscle twitching—Liothyronine—hypothyroidism	0.0111	0.0482	CcSEcCtD
Dextroamphetamine—Acute coronary syndrome—Liothyronine—hypothyroidism	0.00603	0.0261	CcSEcCtD
Dextroamphetamine—Myocardial infarction—Liothyronine—hypothyroidism	0.006	0.026	CcSEcCtD
Dextroamphetamine—SLC18A2—Amine compound SLC transporters—SLC5A7—hypothyroidism	0.00553	0.0736	CbGpPWpGaD
Dextroamphetamine—TAAR1—thyroid gland—hypothyroidism	0.00456	0.125	CbGeAlD
Dextroamphetamine—SLC6A3—nerve—hypothyroidism	0.00439	0.12	CbGeAlD
Dextroamphetamine—SLC18A2—Neurotransmitter Release Cycle—SLC5A7—hypothyroidism	0.00422	0.0562	CbGpPWpGaD
Dextroamphetamine—Hypertension—Liothyronine—hypothyroidism	0.00413	0.0179	CcSEcCtD
Dextroamphetamine—Muscle twitching—Liotrix—hypothyroidism	0.00403	0.0174	CcSEcCtD
Dextroamphetamine—Affect lability—Levothyroxine—hypothyroidism	0.00384	0.0166	CcSEcCtD
Dextroamphetamine—Affect lability—Dextrothyroxine—hypothyroidism	0.00384	0.0166	CcSEcCtD
Dextroamphetamine—Tachycardia—Liothyronine—hypothyroidism	0.00381	0.0165	CcSEcCtD
Dextroamphetamine—Irritability—Dextrothyroxine—hypothyroidism	0.00372	0.0161	CcSEcCtD
Dextroamphetamine—Irritability—Levothyroxine—hypothyroidism	0.00372	0.0161	CcSEcCtD
Dextroamphetamine—SLC6A2—Amine compound SLC transporters—SLC5A7—hypothyroidism	0.00372	0.0495	CbGpPWpGaD
Dextroamphetamine—Mood swings—Dextrothyroxine—hypothyroidism	0.0037	0.016	CcSEcCtD
Dextroamphetamine—Mood swings—Levothyroxine—hypothyroidism	0.0037	0.016	CcSEcCtD
Dextroamphetamine—SLC6A2—nerve—hypothyroidism	0.00354	0.0966	CbGeAlD
Dextroamphetamine—Lightheadedness—Liotrix—hypothyroidism	0.00354	0.0153	CcSEcCtD
Dextroamphetamine—SLC6A2—Monoamine Transport—SLC5A7—hypothyroidism	0.00353	0.047	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Amine compound SLC transporters—SLC5A7—hypothyroidism	0.00329	0.0439	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Monoamine Transport—SLC5A7—hypothyroidism	0.00313	0.0417	CbGpPWpGaD
Dextroamphetamine—Body temperature increased—Liothyronine—hypothyroidism	0.00309	0.0134	CcSEcCtD
Dextroamphetamine—Weight decreased—Dextrothyroxine—hypothyroidism	0.00305	0.0132	CcSEcCtD
Dextroamphetamine—Weight decreased—Levothyroxine—hypothyroidism	0.00305	0.0132	CcSEcCtD
Dextroamphetamine—Acute coronary syndrome—Levothyroxine—hypothyroidism	0.00296	0.0128	CcSEcCtD
Dextroamphetamine—Acute coronary syndrome—Dextrothyroxine—hypothyroidism	0.00296	0.0128	CcSEcCtD
Dextroamphetamine—Myocardial infarction—Levothyroxine—hypothyroidism	0.00295	0.0128	CcSEcCtD
Dextroamphetamine—Myocardial infarction—Dextrothyroxine—hypothyroidism	0.00295	0.0128	CcSEcCtD
Dextroamphetamine—Cerebrovascular accident—Liotrix—hypothyroidism	0.00293	0.0127	CcSEcCtD
Dextroamphetamine—Sweating—Dextrothyroxine—hypothyroidism	0.00288	0.0125	CcSEcCtD
Dextroamphetamine—Sweating—Levothyroxine—hypothyroidism	0.00288	0.0125	CcSEcCtD
Dextroamphetamine—Affect lability—Liotrix—hypothyroidism	0.00282	0.0122	CcSEcCtD
Dextroamphetamine—CYP2D6—urine—hypothyroidism	0.00281	0.0766	CbGeAlD
Dextroamphetamine—Irritability—Liotrix—hypothyroidism	0.00274	0.0119	CcSEcCtD
Dextroamphetamine—Mood swings—Liotrix—hypothyroidism	0.00272	0.0118	CcSEcCtD
Dextroamphetamine—SLC18A2—Synaptic Vesicle Pathway—CLTC—hypothyroidism	0.00251	0.0334	CbGpPWpGaD
Dextroamphetamine—Tension—Levothyroxine—hypothyroidism	0.00231	0.00998	CcSEcCtD
Dextroamphetamine—Tension—Dextrothyroxine—hypothyroidism	0.00231	0.00998	CcSEcCtD
Dextroamphetamine—Nervousness—Levothyroxine—hypothyroidism	0.00228	0.00988	CcSEcCtD
Dextroamphetamine—Nervousness—Dextrothyroxine—hypothyroidism	0.00228	0.00988	CcSEcCtD
Dextroamphetamine—Weight decreased—Liotrix—hypothyroidism	0.00224	0.00971	CcSEcCtD
Dextroamphetamine—Tremor—Levothyroxine—hypothyroidism	0.0022	0.00953	CcSEcCtD
Dextroamphetamine—Tremor—Dextrothyroxine—hypothyroidism	0.0022	0.00953	CcSEcCtD
Dextroamphetamine—Acute coronary syndrome—Liotrix—hypothyroidism	0.00218	0.00944	CcSEcCtD
Dextroamphetamine—Myocardial infarction—Liotrix—hypothyroidism	0.00217	0.00938	CcSEcCtD
Dextroamphetamine—SLC18A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC5A7—hypothyroidism	0.00216	0.0288	CbGpPWpGaD
Dextroamphetamine—Agitation—Levothyroxine—hypothyroidism	0.00216	0.00935	CcSEcCtD
Dextroamphetamine—Agitation—Dextrothyroxine—hypothyroidism	0.00216	0.00935	CcSEcCtD
Dextroamphetamine—Angioedema—Dextrothyroxine—hypothyroidism	0.00215	0.00929	CcSEcCtD
Dextroamphetamine—Angioedema—Levothyroxine—hypothyroidism	0.00215	0.00929	CcSEcCtD
Dextroamphetamine—Sweating—Liotrix—hypothyroidism	0.00212	0.00918	CcSEcCtD
Dextroamphetamine—Palpitations—Levothyroxine—hypothyroidism	0.00208	0.00899	CcSEcCtD
Dextroamphetamine—Palpitations—Dextrothyroxine—hypothyroidism	0.00208	0.00899	CcSEcCtD
Dextroamphetamine—Convulsion—Levothyroxine—hypothyroidism	0.00204	0.00881	CcSEcCtD
Dextroamphetamine—Convulsion—Dextrothyroxine—hypothyroidism	0.00204	0.00881	CcSEcCtD
Dextroamphetamine—Anxiety—Dextrothyroxine—hypothyroidism	0.00199	0.00863	CcSEcCtD
Dextroamphetamine—Anxiety—Levothyroxine—hypothyroidism	0.00199	0.00863	CcSEcCtD
Dextroamphetamine—TAAR1—G alpha (s) signalling events—TSHB—hypothyroidism	0.00195	0.0259	CbGpPWpGaD
Dextroamphetamine—TAAR1—G alpha (s) signalling events—TSHR—hypothyroidism	0.00195	0.0259	CbGpPWpGaD
Dextroamphetamine—Tachycardia—Levothyroxine—hypothyroidism	0.00187	0.0081	CcSEcCtD
Dextroamphetamine—Tachycardia—Dextrothyroxine—hypothyroidism	0.00187	0.0081	CcSEcCtD
Dextroamphetamine—Hyperhidrosis—Levothyroxine—hypothyroidism	0.00185	0.00803	CcSEcCtD
Dextroamphetamine—Hyperhidrosis—Dextrothyroxine—hypothyroidism	0.00185	0.00803	CcSEcCtD
Dextroamphetamine—Insomnia—Levothyroxine—hypothyroidism	0.00173	0.00751	CcSEcCtD
Dextroamphetamine—Insomnia—Dextrothyroxine—hypothyroidism	0.00173	0.00751	CcSEcCtD
Dextroamphetamine—Dyspnoea—Levothyroxine—hypothyroidism	0.00171	0.0074	CcSEcCtD
Dextroamphetamine—Dyspnoea—Dextrothyroxine—hypothyroidism	0.00171	0.0074	CcSEcCtD
Dextroamphetamine—Tension—Liotrix—hypothyroidism	0.0017	0.00734	CcSEcCtD
Dextroamphetamine—Nervousness—Liotrix—hypothyroidism	0.00168	0.00727	CcSEcCtD
Dextroamphetamine—Fatigue—Dextrothyroxine—hypothyroidism	0.00165	0.00716	CcSEcCtD
Dextroamphetamine—Fatigue—Levothyroxine—hypothyroidism	0.00165	0.00716	CcSEcCtD
Dextroamphetamine—Tremor—Liotrix—hypothyroidism	0.00162	0.00701	CcSEcCtD
Dextroamphetamine—SLC18A2—adrenal gland—hypothyroidism	0.00161	0.0439	CbGeAlD
Dextroamphetamine—SLC18A2—blood—hypothyroidism	0.00161	0.0438	CbGeAlD
Dextroamphetamine—Agitation—Liotrix—hypothyroidism	0.00159	0.00688	CcSEcCtD
Dextroamphetamine—Angioedema—Liotrix—hypothyroidism	0.00158	0.00684	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Dextrothyroxine—hypothyroidism	0.00157	0.00679	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Levothyroxine—hypothyroidism	0.00157	0.00679	CcSEcCtD
Dextroamphetamine—SLC18A2—thyroid gland—hypothyroidism	0.00155	0.0423	CbGeAlD
Dextroamphetamine—Palpitations—Liotrix—hypothyroidism	0.00153	0.00661	CcSEcCtD
Dextroamphetamine—Urticaria—Levothyroxine—hypothyroidism	0.00152	0.00659	CcSEcCtD
Dextroamphetamine—Urticaria—Dextrothyroxine—hypothyroidism	0.00152	0.00659	CcSEcCtD
Dextroamphetamine—Abdominal pain—Dextrothyroxine—hypothyroidism	0.00152	0.00656	CcSEcCtD
Dextroamphetamine—Body temperature increased—Levothyroxine—hypothyroidism	0.00152	0.00656	CcSEcCtD
Dextroamphetamine—Body temperature increased—Dextrothyroxine—hypothyroidism	0.00152	0.00656	CcSEcCtD
Dextroamphetamine—Abdominal pain—Levothyroxine—hypothyroidism	0.00152	0.00656	CcSEcCtD
Dextroamphetamine—Convulsion—Liotrix—hypothyroidism	0.0015	0.00648	CcSEcCtD
Dextroamphetamine—Hypertension—Liotrix—hypothyroidism	0.00149	0.00646	CcSEcCtD
Dextroamphetamine—Chest pain—Liotrix—hypothyroidism	0.00147	0.00637	CcSEcCtD
Dextroamphetamine—Anxiety—Liotrix—hypothyroidism	0.00147	0.00635	CcSEcCtD
Dextroamphetamine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC5A7—hypothyroidism	0.00145	0.0194	CbGpPWpGaD
Dextroamphetamine—Anaphylactic shock—Liotrix—hypothyroidism	0.00141	0.00611	CcSEcCtD
Dextroamphetamine—Infection—Liotrix—hypothyroidism	0.0014	0.00607	CcSEcCtD
Dextroamphetamine—Tachycardia—Liotrix—hypothyroidism	0.00138	0.00596	CcSEcCtD
Dextroamphetamine—Asthenia—Dextrothyroxine—hypothyroidism	0.00138	0.00596	CcSEcCtD
Dextroamphetamine—Asthenia—Levothyroxine—hypothyroidism	0.00138	0.00596	CcSEcCtD
Dextroamphetamine—Hyperhidrosis—Liotrix—hypothyroidism	0.00136	0.0059	CcSEcCtD
Dextroamphetamine—Anorexia—Liotrix—hypothyroidism	0.00134	0.00582	CcSEcCtD
Dextroamphetamine—SLC18A2—testis—hypothyroidism	0.00133	0.0363	CbGeAlD
Dextroamphetamine—Diarrhoea—Dextrothyroxine—hypothyroidism	0.00131	0.00568	CcSEcCtD
Dextroamphetamine—Diarrhoea—Levothyroxine—hypothyroidism	0.00131	0.00568	CcSEcCtD
Dextroamphetamine—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC5A7—hypothyroidism	0.00129	0.0172	CbGpPWpGaD
Dextroamphetamine—Insomnia—Liotrix—hypothyroidism	0.00128	0.00552	CcSEcCtD
Dextroamphetamine—Dyspnoea—Liotrix—hypothyroidism	0.00126	0.00544	CcSEcCtD
Dextroamphetamine—SLC18A2—liver—hypothyroidism	0.00126	0.0343	CbGeAlD
Dextroamphetamine—SLC18A2—cerebellum—hypothyroidism	0.00123	0.0335	CbGeAlD
Dextroamphetamine—Decreased appetite—Liotrix—hypothyroidism	0.00123	0.00531	CcSEcCtD
Dextroamphetamine—ADRA1A—heart—hypothyroidism	0.00122	0.0333	CbGeAlD
Dextroamphetamine—Vomiting—Dextrothyroxine—hypothyroidism	0.00122	0.00528	CcSEcCtD
Dextroamphetamine—Vomiting—Levothyroxine—hypothyroidism	0.00122	0.00528	CcSEcCtD
Dextroamphetamine—Fatigue—Liotrix—hypothyroidism	0.00122	0.00526	CcSEcCtD
Dextroamphetamine—SLC18A2—Transmission across Chemical Synapses—SLC5A7—hypothyroidism	0.00121	0.0161	CbGpPWpGaD
Dextroamphetamine—Rash—Dextrothyroxine—hypothyroidism	0.00121	0.00523	CcSEcCtD
Dextroamphetamine—Rash—Levothyroxine—hypothyroidism	0.00121	0.00523	CcSEcCtD
Dextroamphetamine—Dermatitis—Dextrothyroxine—hypothyroidism	0.00121	0.00523	CcSEcCtD
Dextroamphetamine—Dermatitis—Levothyroxine—hypothyroidism	0.00121	0.00523	CcSEcCtD
Dextroamphetamine—Constipation—Liotrix—hypothyroidism	0.00121	0.00522	CcSEcCtD
Dextroamphetamine—Headache—Dextrothyroxine—hypothyroidism	0.0012	0.0052	CcSEcCtD
Dextroamphetamine—Headache—Levothyroxine—hypothyroidism	0.0012	0.0052	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Liotrix—hypothyroidism	0.00115	0.00499	CcSEcCtD
Dextroamphetamine—ADRA1A—cardiovascular system—hypothyroidism	0.00115	0.0315	CbGeAlD
Dextroamphetamine—TAAR1—G alpha (s) signalling events—AVP—hypothyroidism	0.00115	0.0153	CbGpPWpGaD
Dextroamphetamine—Nausea—Dextrothyroxine—hypothyroidism	0.00114	0.00493	CcSEcCtD
Dextroamphetamine—Nausea—Levothyroxine—hypothyroidism	0.00114	0.00493	CcSEcCtD
Dextroamphetamine—SLC6A2—gonad—hypothyroidism	0.00113	0.0307	CbGeAlD
Dextroamphetamine—Urticaria—Liotrix—hypothyroidism	0.00112	0.00485	CcSEcCtD
Dextroamphetamine—Abdominal pain—Liotrix—hypothyroidism	0.00111	0.00483	CcSEcCtD
Dextroamphetamine—Body temperature increased—Liotrix—hypothyroidism	0.00111	0.00483	CcSEcCtD
Dextroamphetamine—SLC6A2—NRF2 pathway—SLC5A7—hypothyroidism	0.00105	0.014	CbGpPWpGaD
Dextroamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—TRH—hypothyroidism	0.00104	0.0139	CbGpPWpGaD
Dextroamphetamine—Hypersensitivity—Liotrix—hypothyroidism	0.00104	0.0045	CcSEcCtD
Dextroamphetamine—Asthenia—Liotrix—hypothyroidism	0.00101	0.00438	CcSEcCtD
Dextroamphetamine—SLC6A3—testis—hypothyroidism	0.00101	0.0274	CbGeAlD
Dextroamphetamine—SLC18A2—SLC-mediated transmembrane transport—SLC5A7—hypothyroidism	0.000982	0.0131	CbGpPWpGaD
Dextroamphetamine—SLC6A2—adrenal gland—hypothyroidism	0.000981	0.0268	CbGeAlD
Dextroamphetamine—Diarrhoea—Liotrix—hypothyroidism	0.000965	0.00418	CcSEcCtD
Dextroamphetamine—Dizziness—Liotrix—hypothyroidism	0.000933	0.00404	CcSEcCtD
Dextroamphetamine—SLC6A3—NRF2 pathway—SLC5A7—hypothyroidism	0.000929	0.0124	CbGpPWpGaD
Dextroamphetamine—SLC6A3—cerebellum—hypothyroidism	0.000928	0.0253	CbGeAlD
Dextroamphetamine—SLC18A2—Neuronal System—SLC5A7—hypothyroidism	0.000928	0.0124	CbGpPWpGaD
Dextroamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—TSHB—hypothyroidism	0.000928	0.0124	CbGpPWpGaD
Dextroamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—TSHR—hypothyroidism	0.000928	0.0124	CbGpPWpGaD
Dextroamphetamine—ADRA1A—adrenal gland—hypothyroidism	0.000912	0.0249	CbGeAlD
Dextroamphetamine—ADRA1A—blood—hypothyroidism	0.000912	0.0249	CbGeAlD
Dextroamphetamine—Vomiting—Liotrix—hypothyroidism	0.000897	0.00388	CcSEcCtD
Dextroamphetamine—Rash—Liotrix—hypothyroidism	0.000889	0.00385	CcSEcCtD
Dextroamphetamine—Dermatitis—Liotrix—hypothyroidism	0.000888	0.00385	CcSEcCtD
Dextroamphetamine—Headache—Liotrix—hypothyroidism	0.000883	0.00383	CcSEcCtD
Dextroamphetamine—Nausea—Liotrix—hypothyroidism	0.000838	0.00363	CcSEcCtD
Dextroamphetamine—SLC18A2—SLC-mediated transmembrane transport—SLC26A4—hypothyroidism	0.000814	0.0108	CbGpPWpGaD
Dextroamphetamine—SLC6A2—testis—hypothyroidism	0.000811	0.0221	CbGeAlD
Dextroamphetamine—TAAR1—GPCR ligand binding—TRH—hypothyroidism	0.000793	0.0106	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmission across Chemical Synapses—NEFL—hypothyroidism	0.000781	0.0104	CbGpPWpGaD
Dextroamphetamine—TAAR1—G alpha (s) signalling events—POMC—hypothyroidism	0.000762	0.0102	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmission across Chemical Synapses—SLC5A7—hypothyroidism	0.000722	0.00962	CbGpPWpGaD
Dextroamphetamine—ADRA1A—liver—hypothyroidism	0.000713	0.0195	CbGeAlD
Dextroamphetamine—TAAR1—GPCR ligand binding—TSHR—hypothyroidism	0.000707	0.00941	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR ligand binding—TSHB—hypothyroidism	0.000707	0.00941	CbGpPWpGaD
Dextroamphetamine—ADRA1A—cerebellum—hypothyroidism	0.000696	0.019	CbGeAlD
Dextroamphetamine—SLC6A2—SLC-mediated transmembrane transport—SLC5A7—hypothyroidism	0.000661	0.0088	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Neuronal System—NEFL—hypothyroidism	0.000598	0.00797	CbGpPWpGaD
Dextroamphetamine—SLC6A3—SLC-mediated transmembrane transport—SLC5A7—hypothyroidism	0.000586	0.0078	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Neuronal System—SLC5A7—hypothyroidism	0.000553	0.00737	CbGpPWpGaD
Dextroamphetamine—SLC6A2—SLC-mediated transmembrane transport—SLC26A4—hypothyroidism	0.000548	0.00729	CbGpPWpGaD
Dextroamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—AVP—hypothyroidism	0.000547	0.00728	CbGpPWpGaD
Dextroamphetamine—CYP2D6—blood—hypothyroidism	0.000537	0.0146	CbGeAlD
Dextroamphetamine—CYP2D6—female gonad—hypothyroidism	0.000501	0.0137	CbGeAlD
Dextroamphetamine—SLC18A2—Transmembrane transport of small molecules—SLC5A7—hypothyroidism	0.000499	0.00665	CbGpPWpGaD
Dextroamphetamine—SLC6A3—SLC-mediated transmembrane transport—SLC26A4—hypothyroidism	0.000485	0.00646	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmission across Chemical Synapses—NEFL—hypothyroidism	0.000465	0.0062	CbGpPWpGaD
Dextroamphetamine—ADRA1B—G alpha (12/13) signalling events—VAV3—hypothyroidism	0.00045	0.006	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—TRH—hypothyroidism	0.000448	0.00597	CbGpPWpGaD
Dextroamphetamine—CYP2D6—testis—hypothyroidism	0.000444	0.0121	CbGeAlD
Dextroamphetamine—CYP2D6—liver—hypothyroidism	0.00042	0.0115	CbGeAlD
Dextroamphetamine—SLC6A2—NRF2 pathway—SLC5A5—hypothyroidism	0.000419	0.00558	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR ligand binding—AVP—hypothyroidism	0.000417	0.00555	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmembrane transport of small molecules—SLC26A4—hypothyroidism	0.000414	0.00551	CbGpPWpGaD
Dextroamphetamine—CYP2D6—cerebellum—hypothyroidism	0.00041	0.0112	CbGeAlD
Dextroamphetamine—TAAR1—Signaling by GPCR—TRH—hypothyroidism	0.000407	0.00542	CbGpPWpGaD
Dextroamphetamine—ADRA1A—G alpha (12/13) signalling events—VAV3—hypothyroidism	0.0004	0.00533	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—TSHB—hypothyroidism	0.000399	0.00532	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—TSHR—hypothyroidism	0.000399	0.00532	CbGpPWpGaD
Dextroamphetamine—ADRA1B—G alpha (q) signalling events—TRH—hypothyroidism	0.000398	0.0053	CbGpPWpGaD
Dextroamphetamine—SLC18A2—SLC-mediated transmembrane transport—SLC5A5—hypothyroidism	0.000393	0.00523	CbGpPWpGaD
Dextroamphetamine—SLC6A3—NRF2 pathway—SLC5A5—hypothyroidism	0.000371	0.00495	CbGpPWpGaD
Dextroamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—POMC—hypothyroidism	0.000363	0.00484	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—TSHB—hypothyroidism	0.000363	0.00483	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—TSHR—hypothyroidism	0.000363	0.00483	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Neuronal System—NEFL—hypothyroidism	0.000357	0.00475	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—TRH—hypothyroidism	0.000356	0.00474	CbGpPWpGaD
Dextroamphetamine—ADRA1A—G alpha (q) signalling events—TRH—hypothyroidism	0.000353	0.0047	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—SLC5A7—hypothyroidism	0.000336	0.00447	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—TRH—hypothyroidism	0.000316	0.00421	CbGpPWpGaD
Dextroamphetamine—SLC18A2—SLC-mediated transmembrane transport—AVP—hypothyroidism	0.000309	0.00412	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—SLC5A7—hypothyroidism	0.000298	0.00396	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—SLC26A4—hypothyroidism	0.000278	0.00371	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—CLTC—hypothyroidism	0.000278	0.0037	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR ligand binding—POMC—hypothyroidism	0.000277	0.00369	CbGpPWpGaD
Dextroamphetamine—SLC6A2—SLC-mediated transmembrane transport—SLC5A5—hypothyroidism	0.000264	0.00352	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—TRH—hypothyroidism	0.000263	0.00351	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—SLC26A4—hypothyroidism	0.000247	0.00328	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—VAV3—hypothyroidism	0.000244	0.00325	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—TRH—hypothyroidism	0.00024	0.0032	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—AVP—hypothyroidism	0.000235	0.00313	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—TSHB—hypothyroidism	0.000235	0.00313	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—TSHR—hypothyroidism	0.000235	0.00313	CbGpPWpGaD
Dextroamphetamine—SLC6A3—SLC-mediated transmembrane transport—SLC5A5—hypothyroidism	0.000234	0.00312	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—TRH—hypothyroidism	0.000234	0.00312	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—VAV3—hypothyroidism	0.000222	0.00295	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—TSHB—hypothyroidism	0.000214	0.00285	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—TSHR—hypothyroidism	0.000214	0.00285	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—AVP—hypothyroidism	0.000214	0.00285	CbGpPWpGaD
Dextroamphetamine—ADRA1B—G alpha (q) signalling events—AVP—hypothyroidism	0.000209	0.00278	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—TSHR—hypothyroidism	0.000209	0.00278	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—TSHB—hypothyroidism	0.000209	0.00278	CbGpPWpGaD
Dextroamphetamine—SLC6A2—SLC-mediated transmembrane transport—AVP—hypothyroidism	0.000208	0.00277	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—TRH—hypothyroidism	0.000201	0.00267	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmembrane transport of small molecules—SLC5A5—hypothyroidism	0.0002	0.00266	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—SH2B3—hypothyroidism	0.000191	0.00254	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—AVP—hypothyroidism	0.000187	0.00249	CbGpPWpGaD
Dextroamphetamine—ADRA1A—G alpha (q) signalling events—AVP—hypothyroidism	0.000186	0.00247	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Cytochrome P450 - arranged by substrate type—POMC—hypothyroidism	0.000185	0.00247	CbGpPWpGaD
Dextroamphetamine—SLC6A3—SLC-mediated transmembrane transport—AVP—hypothyroidism	0.000184	0.00245	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—TSHB—hypothyroidism	0.000179	0.00238	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—TSHR—hypothyroidism	0.000179	0.00238	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—TRH—hypothyroidism	0.000178	0.00237	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—AVP—hypothyroidism	0.000166	0.00221	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—TSHB—hypothyroidism	0.000159	0.00211	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—TSHR—hypothyroidism	0.000159	0.00211	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmembrane transport of small molecules—AVP—hypothyroidism	0.000157	0.00209	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—POMC—hypothyroidism	0.000156	0.00208	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	0.00015	0.002	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—POMC—hypothyroidism	0.000142	0.00189	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—PRL—hypothyroidism	0.000142	0.00189	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—AVP—hypothyroidism	0.000138	0.00184	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—SLC5A5—hypothyroidism	0.000134	0.00179	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—VAV3—hypothyroidism	0.000131	0.00175	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—AVP—hypothyroidism	0.000126	0.00168	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—AVP—hypothyroidism	0.000123	0.00164	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—SLC5A5—hypothyroidism	0.000119	0.00158	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—TRH—hypothyroidism	0.000113	0.00151	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—AVP—hypothyroidism	0.000106	0.00141	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—AVP—hypothyroidism	0.000105	0.0014	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—TRH—hypothyroidism	0.000103	0.00137	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—TSHB—hypothyroidism	0.000101	0.00135	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—TSHR—hypothyroidism	0.000101	0.00135	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—TRH—hypothyroidism	0.000101	0.00134	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—IYD—hypothyroidism	9.42e-05	0.00125	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—AVP—hypothyroidism	9.36e-05	0.00125	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—AVP—hypothyroidism	9.36e-05	0.00125	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—POMC—hypothyroidism	9.19e-05	0.00122	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—TSHB—hypothyroidism	9.17e-05	0.00122	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—TSHR—hypothyroidism	9.17e-05	0.00122	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—TRH—hypothyroidism	9.14e-05	0.00122	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—TSHB—hypothyroidism	8.97e-05	0.00119	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—TSHR—hypothyroidism	8.97e-05	0.00119	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—POMC—hypothyroidism	8.39e-05	0.00112	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—POMC—hypothyroidism	8.17e-05	0.00109	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—TSHB—hypothyroidism	8.15e-05	0.00109	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—TSHR—hypothyroidism	8.15e-05	0.00109	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—IGF1—hypothyroidism	8.07e-05	0.00107	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—ATP5O—hypothyroidism	8.01e-05	0.00107	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Biological oxidations—POMC—hypothyroidism	7.98e-05	0.00106	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—TPO—hypothyroidism	7.53e-05	0.001	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CLTC—hypothyroidism	7.04e-05	0.000937	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—POMC—hypothyroidism	7e-05	0.000932	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CLTC—hypothyroidism	6.25e-05	0.000832	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—POMC—hypothyroidism	6.22e-05	0.000828	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—VAV3—hypothyroidism	6.18e-05	0.000823	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—TRH—hypothyroidism	6.08e-05	0.00081	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—AVP—hypothyroidism	5.95e-05	0.000793	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—VAV3—hypothyroidism	5.61e-05	0.000747	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—VAV3—hypothyroidism	5.49e-05	0.000731	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—TSHB—hypothyroidism	5.42e-05	0.000722	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—TSHR—hypothyroidism	5.42e-05	0.000722	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—AVP—hypothyroidism	5.41e-05	0.00072	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—TRH—hypothyroidism	5.4e-05	0.000719	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—AVP—hypothyroidism	5.29e-05	0.000704	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—VAV3—hypothyroidism	4.98e-05	0.000664	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—SH2B3—hypothyroidism	4.83e-05	0.000643	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—TSHB—hypothyroidism	4.81e-05	0.000641	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—TSHR—hypothyroidism	4.81e-05	0.000641	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—AVP—hypothyroidism	4.8e-05	0.00064	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—SH2B3—hypothyroidism	4.29e-05	0.000571	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—POMC—hypothyroidism	3.96e-05	0.000527	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—POMC—hypothyroidism	3.59e-05	0.000478	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PRL—hypothyroidism	3.58e-05	0.000477	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—POMC—hypothyroidism	3.51e-05	0.000468	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—TSHB—hypothyroidism	3.49e-05	0.000464	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—VAV3—hypothyroidism	3.32e-05	0.000441	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—AVP—hypothyroidism	3.19e-05	0.000425	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—POMC—hypothyroidism	3.19e-05	0.000425	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PRL—hypothyroidism	3.18e-05	0.000424	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—PIK3C2A—hypothyroidism	3.11e-05	0.000414	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—VAV3—hypothyroidism	2.94e-05	0.000392	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—AVP—hypothyroidism	2.84e-05	0.000378	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—SLC5A5—hypothyroidism	2.61e-05	0.000347	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—POMC—hypothyroidism	2.12e-05	0.000283	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—IGF1—hypothyroidism	2.04e-05	0.000272	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—POMC—hypothyroidism	1.89e-05	0.000251	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—IGF1—hypothyroidism	1.81e-05	0.000242	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—POMC—hypothyroidism	1.37e-05	0.000182	CbGpPWpGaD
